loading
前日終値:
$155.92
開ける:
$155.92
24時間の取引高:
812.95K
Relative Volume:
0.65
時価総額:
$15.66B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
23.69
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+0.98%
1か月 パフォーマンス:
-15.74%
6か月 パフォーマンス:
+16.49%
1年 パフォーマンス:
+10.88%
1日の値動き範囲:
Value
$153.08
$156.57
1週間の範囲:
Value
$151.77
$159.40
52週間の値動き範囲:
Value
$122.14
$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1080)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-07-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
154.06 15.55B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.03 57.90B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
10.11 43.41B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
36.44 42.89B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
77.34 31.00B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
515.46 22.35B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Aug 20, 2026

Zacks Investment ResearchGlobes - Globes - Israel Business News

Aug 20, 2026
pulisher
Aug 20, 2026

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore

Aug 20, 2026
pulisher
Aug 18, 2026

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st

Aug 18, 2026
pulisher
Aug 18, 2026

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits

Aug 18, 2026
pulisher
Aug 17, 2026

GlobesIsrael Business News - גלובס

Aug 17, 2026
pulisher
Aug 17, 2026

Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Aug 17, 2026
pulisher
Aug 17, 2026

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance

Aug 17, 2026
pulisher
Aug 17, 2026

Neurocrine Biosciences Rings the Opening Bell - Nasdaq

Aug 17, 2026
pulisher
Aug 16, 2026

Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st

Aug 16, 2026
pulisher
Aug 15, 2026

NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Aug 15, 2026
pulisher
Aug 15, 2026

Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals

Aug 14, 2026
pulisher
Aug 14, 2026

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters

Aug 14, 2026
pulisher
Aug 13, 2026

Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com

Aug 13, 2026
pulisher
Aug 13, 2026

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance

Aug 12, 2026
pulisher
Aug 12, 2026

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Yahoo Finance

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences Inc (NBIX) Shares Fall 3.4% -- What GF Sc - GuruFocus

Aug 12, 2026
pulisher
Aug 12, 2026

Why is Neurocrine Biosciences stock sliding today? By Investing.com - Investing.com Canada

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences (NBIX) Dips 3%: Stock Holds Above Key Support at $156.99Quality Factor - Vinanet

Aug 12, 2026
pulisher
Aug 12, 2026

Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative

Aug 12, 2026
pulisher
Aug 12, 2026

What's Going On With Neurocrine Biosciences Stock On Wednesday? - Benzinga

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine down on safety events linked to Vykat (NBIX:NASDAQ) - Seeking Alpha

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences shares fall amid Vykat safety concerns - Yahoo Finance

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences stock falls on Vykat safety concerns By Investing.com - Investing.com Canada

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences stock falls on Vykat safety concerns - Investing.com

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms - Investing.com

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine's INGREZZA Study Reports Better Daily Function in TD - Stock Titan

Aug 12, 2026
pulisher
Aug 12, 2026

Why is Neurocrine Biosciences stock down today? By Investing.com - Investing.com Australia

Aug 12, 2026
pulisher
Aug 12, 2026

Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Neurocrine Biosciences (NBIX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Aug 12, 2026
pulisher
Aug 11, 2026

Liquidity Mapping Around (NBIX) Price Events - Stock Traders Daily

Aug 11, 2026
pulisher
Aug 11, 2026

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing? - Sahm

Aug 11, 2026
pulisher
Aug 11, 2026

Neurocrine Initiates Phase I Trial of Triple Agonist NBIP-’1968 for Obesity - BioPharma APAC

Aug 11, 2026
pulisher
Aug 10, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews

Aug 10, 2026
pulisher
Aug 10, 2026

Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com

Aug 10, 2026
pulisher
Aug 09, 2026

Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 09, 2026
pulisher
Aug 09, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 09, 2026
pulisher
Aug 08, 2026

Neurocrine Biosciences, Inc. (NB3.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia

Aug 08, 2026
pulisher
Aug 08, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat

Aug 08, 2026
pulisher
Aug 08, 2026

Healthcare Stocks Investors Are Watching For Steady Demand After Weak US Jobs Data - Sahm

Aug 08, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$16.34
price down icon 3.26%
$24.11
price down icon 1.55%
RDY RDY
$12.18
price up icon 0.16%
$515.46
price down icon 2.36%
$47.41
price down icon 3.05%
大文字化:     |  ボリューム (24 時間):